Pfizer $PFE
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS126
PHASE 3 / 2-393
RECRUITING78
READOUTS ≤12 MONTHS35
READOUT SLIPPED >6 MO53%
Delay Index: of 81 active trials registered more than a year ago, 43 have moved their primary completion (readout) date by more than 6 months since first registration (median +6.2 months). See all sponsors →
Open Pfizer on the live radar map → 📅 $PFE readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Lorlatinib NCT03052608 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 296 | 2020-03-20 (+4 mo) |
| TALAPRO-2 NCT03395197 |
P3 | Active, not recruiting | mCRPC | 1054 | 2022-10-03 (+6 mo) |
| BENEGENE-2 NCT03861273 |
P3 | Active, not recruiting | Hemophilia B | 51 | 2022-11-16 (+10 mo) |
| Enzalutamide NCT02319837 |
P3 | Active, not recruiting | Hormone Sensitive Prostate Cancer; Prostate Cancer | 1068 | 2023-01-31 (+26 mo) |
| Tucatinib NCT04721977 |
P2 | Active, not recruiting | Breast Cancer | 66 | 2023-07-17 (+6 mo) |
| PF-06939926 NCT04281485 |
P3 | Active, not recruiting | Duchenne Muscular Dystrophy | 114 | 2024-05-15 (+25 mo) |
| AFFINE NCT04370054 |
P3 | Active, not recruiting | Hemophilia A | 77 | 2024-06-17 (+22 mo) |
| CREST NCT04165317 |
P3 | Active, not recruiting | Non-muscle Invasive Bladder Cancer | 1068 | 2024-12-02 (+6 mo) |
| VERITAC-2 NCT05654623 |
P3 | Active, not recruiting | Advanced Breast Cancer | 624 | 2025-01-31 (+6 mo) |
| Encorafenib NCT04607421 |
P3 | Active, not recruiting | Neoplasms | 841 | 2025-03-01 (+5 mo) |
| vepdegestrant NCT06206837 |
P1/2 | Active, not recruiting | Breast Cancer | 71 | 2025-09-05 (-8 mo) |
| PF-07220060 CDK4 inhibitor NCT06105632 |
P2 | Active, not recruiting | Advanced or Metastatic Breast Cancer | 333 | 2026-01-12 (+2 mo) |
| talazoparib plus enzalutamide NCT04821622 |
P3 | Active, not recruiting | Prostate Cancer | 599 | 2026-02-18 (+14 mo) |
| MAGNETISMM-5 NCT05020236 |
P3 | Recruiting | Multiple Myeloma | 893 | 2026-02-26 (+10 mo) |
| SEAMARK NCT05217446 |
P2 | Active, not recruiting | Metastatic Colorectal Cancer | 108 | 2026-06-19 (+4 mo) |
| nirmatrelvir NCT05261139 |
P3 | Recruiting | COVID-19 | 160 | 2026-07-30 (+41 mo) |
| Elranatamab NCT06152575 |
P3 | Recruiting | Multiple Myeloma | 492 | 2026-08-26 (+9 mo) |
| Encorafenib NCT04657991 |
P3 | Active, not recruiting | Melanoma | 257 | 2026-10-30 (+38 mo) |
| PF-07275315 NCT05995964 |
P2 | Active, not recruiting | Atopic Dermatitis | 507 | 2026-11-12 (+7 mo) |
| Rimegepant NCT06641466 |
P3 | Recruiting | Menstrual Migraine | 723 | 2026-11-29 (+6 mo) |
| B7981027 NCT07029711 |
P3 | Active, not recruiting | Severe Alopecia Areata | 208 | 2026-12-02 (-5 mo) |
| VLA15 NCT07500506 |
P3 | Recruiting | Lyme Disease | 1712 | 2026-12-04 |
| Ritlecitinib NCT07228390 |
P2 | Active, not recruiting | Hidradenitis Suppurativa | 128 | 2026-12-08 (-3 mo) |
| Ritlecitinib 50 mg NCT07219615 |
P2 | Recruiting | Chronic Spontaneous Urticaria | 200 | 2026-12-25 |
| VERITAC-3 NCT05909397 |
P3 | Active, not recruiting | Breast Cancer | 59 | 2026-12-30 (-20 mo) |
| Avelumab NCT05059522 |
P3 | Active, not recruiting | Advanced Malignancies; NSCLC | 77 | 2026-12-31 (+12 mo) |
| PF-07104091 monotherapy dose escalation NCT04553133 |
P2 | Active, not recruiting | Small Cell Lung Cancer; Ovarian Cancer | 157 | 2026-12-31 (+20 mo) |
| RENOIR NCT05035212 |
P3 | Active, not recruiting | Lower Respiratory Tract Illness | 38861 | 2027-01-18 (+31 mo) |
| RSVpreF NCT07653100 |
P3 | Recruiting | Respiratory Syncytial Virus (RSV) | 540 | 2027-01-25 |
| PF-07220060 + PF-07104091 combination dose escalation NCT05262400 |
P1/2 | Active, not recruiting | Breast Cancer; Solid Tumors | 235 | 2027-02-26 (+4 mo) |
| MEVPRO-1 NCT06551324 |
P3 | Active, not recruiting | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | 609 | 2027-02-28 (+14 mo) |
| PG4 NCT06524414 |
P2 | Active, not recruiting | Pneumococcal Disease | 605 | 2027-03-04 (+8 mo) |
| PF-07275315 NCT06977581 |
P2 | Recruiting | Asthma | 252 | 2027-03-08 |
| tofacitinib NCT04624230 |
P3 | Active, not recruiting | Ulcerative Colitis | 118 | 2027-03-17 (+15 mo) |
| ARV-471 NCT05548127 |
P1/2 | Active, not recruiting | Breast Cancer | 37 | 2027-03-24 (+18 mo) |
| ATM-AVI NCT05639647 |
P2 | Recruiting | Gram-negative Bacterial Infections | 48 | 2027-03-31 (+15 mo) |
| Tranquillo LTE NCT06163326 |
P3 | Active, not recruiting | Vitiligo | 394 | 2027-03-31 (+8 mo) |
| CHERISH NCT06462235 |
P2 | Recruiting | Gram-negative Bacterial Infection | 48 | 2027-04-25 (-5 mo) |
| PG4 Multivalent Vaccine NCT07794748 |
P3 | Active, not recruiting | Pneumococcal Disease | 4701 | 2027-04-26 |
| Abrocitinib NCT06807268 |
P3 | Active, not recruiting | Eczema | 151 | 2027-05-02 (+1 mo) |
| RSVpreF NCT07819097 |
P3 | Recruiting | Adult; Healthy Participants | 600 | 2027-05-16 |
| Vaccine Candidate #1 NCT07431853 |
P2 | Recruiting | Healthy Adults | 770 | 2027-06-22 |
| PF-07248144 NCT07062965 |
P3 | Recruiting | Breast Cancer | 400 | 2027-07-22 (-3 mo) |
| Tranquillo 2 NCT06072183 |
P3 | Active, not recruiting | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo | 1571 | 2027-07-30 |
| MagnetisMM-7 NCT05317416 |
P3 | Active, not recruiting | Multiple Myeloma | 854 | 2027-08-04 (+1 mo) |
| SOLIS-1 NCT07575932 |
P2 | Active, not recruiting | Overweight; Obesity | 940 | 2027-08-04 |
| VESPER-4 NCT07311850 |
P3 | Active, not recruiting | Obesity and Overweight | 3578 | 2027-09-21 |
| ibuzatrelvir NCT07013474 |
P3 | Recruiting | COVID-19 Infection | 300 | 2027-09-28 (+10 mo) |
| PF-06821497 NCT06629779 |
P3 | Recruiting | Metastatic Castration-Resistant Prostate Cancer | 900 | 2027-09-30 (+14 mo) |
| ibuzatrelvir NCT06679140 |
P3 | Recruiting | COVID-19 SARS-CoV-2 Infection | 2330 | 2027-10-01 (+10 mo) |
| PF-08653944 NCT07400653 |
P3 | Active, not recruiting | Obesity; Overweight and/or Obesity | 1078 | 2027-10-12 |
| PF-08634404 NCT07227012 |
P1/2 | Recruiting | Carcinoma, Hepatocellular; Hepatocellular Cancer | 138 | 2027-10-18 |
| Disitamab vedotin NCT06966453 |
P1/2 | Active, not recruiting | Breast Cancer; Breast Neoplasms | 74 | 2027-10-25 (+6 mo) |
| PF-08634404 NCT07227415 |
P1/2 | Recruiting | Carcinoma, Renal Cell; Advanced Renal Cell Carcinoma | 224 | 2027-11-02 |
| PG4 NCT07660198 |
P3 | Recruiting | Pneumococcal Disease | 1200 | 2027-12-02 |
| PF-08634404 NCT07421700 |
P1/2 | Recruiting | Urothelial Cancer; Advanced/Metastatic Urothelial Cancer | 132 | 2027-12-28 |
| ponsegromab NCT06989437 |
P2/3 | Recruiting | Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma | 982 | 2028-01-23 (-11 mo) |
| VLA15 NCT07226882 |
P3 | Active, not recruiting | Lyme Borreliosis | 207 | 2028-01-27 |
| PF-08049820 NCT07216027 |
P2 | Recruiting | Atopic Dermatitis; Eczema, Atopic | 165 | 2028-02-02 (+5 mo) |
| RSVpreF Vaccine NCT07768345 |
P3 | Recruiting | Respiratory Syncytial Virus (RSV) | 440 | 2028-02-02 |
| Semaglutide NCT07845500 |
P3 | Recruiting | Obesity; Overweight and/or Obesity | 660 | 2028-02-16 |
| RSVpreF NCT06866405 |
P3 | Recruiting | RSV Infection | 550 | 2028-02-24 |
| Tilrekimig NCT07765888 |
P3 | Recruiting | Atopic Dermatitis | 375 | 2028-03-10 |
| PF-08046054 NCT07144280 |
P3 | Recruiting | Non-small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic | 680 | 2028-03-10 |
| Berobenatide NCT07792954 |
P3 | Recruiting | Obesity; Overweight | 300 | 2028-03-14 |
| ALLEGRO-100 NCT06873945 |
P3 | Recruiting | Alopecia Areata | 674 | 2028-03-19 (+12 mo) |
| PF-08634404 NCT07476287 |
P2 | Recruiting | Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ) | 40 | 2028-03-24 |
| Ritlecitinib 100 mg NCT07733765 |
P3 | Recruiting | Alopecia Areata | 336 | 2028-04-26 |
| Berobenatide NCT07823608 |
P3 | Recruiting | Apnea; Sleep Disorders | 258 | 2028-04-30 |
| PF-08653944 NCT07595549 |
P3 | Recruiting | Obesity; Overweight and/or Obesity | 954 | 2028-05-04 |
| Low Dose PF-07328948 NCT06991257 |
P2 | Recruiting | Heart Failure | 620 | 2028-05-08 (+6 mo) |
| VESPER-OSA 2 NCT07881757 |
P3 | Recruiting | Apnea; Sleep Disorders | 258 | 2028-06-01 |
| Berobenatide NCT07874633 |
P3 | Recruiting | Obesity; Overweight | 432 | 2028-06-06 |
| PF-08634404 NCT07489066 |
P2 | Recruiting | Carcinoma; Non-Small-Cell Lung | 120 | 2028-07-29 |
| Berobenatide NCT07915609 |
P3 | Recruiting | Obesity; Overweight and/or Obesity | 756 | 2028-08-21 |
| Berobenatide NCT07919678 |
P3 | Recruiting | Obesity; Overweight | 656 | 2028-08-22 |
| Sigvotatug Vedotin NCT06758401 |
P3 | Recruiting | Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung | 714 | 2028-09-05 |
| Tilrek NCT07783425 |
P3 | Recruiting | Atopic Dermatitis | 1375 | 2028-09-08 |
| BASIS KIDS NCT05611801 |
P3 | Recruiting | Hemophilia A; Hemophilia B | 100 | 2028-09-10 |
| Mevrometostat NCT07028853 |
P3 | Recruiting | Metastatic Castration Sensitive Prostate Cancer (mCSPC); Hormone Sensitive Prostate Cancer | 1000 | 2028-09-12 |
| Berobenatide NCT07932925 |
P3 | Not yet recruiting | Urinary Incontinence, Stress; Overweight and/or Obesity | 900 | 2028-10-13 |
| Rimegepant NCT07729462 |
P3 | Recruiting | Preventive Treatment of Migraine | 400 | 2028-10-21 |
| Multivalent Group B streptococcus vaccine NCT07160244 |
P3 | Recruiting | Healthy | 6000 | 2028-11-06 |
| 20vPnC NCT07754539 |
P3 | Recruiting | Pneumococcal Diseases | 1250 | 2028-11-30 |
| BEETHOVEN NCT07282665 |
P3 | Recruiting | Clostridoides Difficile Associated Disease | 32500 | 2028-12-11 |
| PG4 NCT07573462 |
P3 | Recruiting | Pneumococcal Disease | 2400 | 2028-12-30 |
| FourLight-3 NCT06760637 |
P3 | Active, not recruiting | Breast Cancer | 1035 | 2029-01-02 |
| Rimegepant/BHV3000 NCT04649242 |
P3 | Recruiting | Pediatric Migraine | 2100 | 2029-01-09 (+72 mo) |
| RSVpreF (Regimen A) NCT07885956 |
P3 | Not yet recruiting | Respiratory Syncytial Virus (RSV) | 750 | 2029-02-07 |
| Berobenatide NCT07794774 |
P3 | Recruiting | Obesity | 197 | 2029-02-21 |
| PF-08634404 NCT07222566 |
P3 | Recruiting | Advanced Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer | 1410 | 2029-02-27 |
| PF-08634404 NCT07227298 |
P1/2 | Recruiting | Advanced/Metastatic Non-Small Cell Lung Cancer; Carcinoma, Non-Small Cell Lung | 162 | 2029-03-08 |
| Berobenatide NCT07794761 |
P3 | Recruiting | Obesity | 180 | 2029-03-14 |
| Rimegepant NCT05156398 |
P3 | Recruiting | Migraine | 640 | 2029-03-27 (+31 mo) |
| Abrocitinib NCT07823595 |
P3 | Not yet recruiting | Atopic Dermatitis | 90 | 2029-04-10 |
| PF-08634404 NCT07578649 |
P3 | Recruiting | Endometrial Neoplasms; Endometrial Cancer | 600 | 2029-06-01 |
| tilrekimig NCT07772921 |
P3 | Recruiting | Asthma | 1100 | 2029-06-01 |
| PG4 NCT07629440 |
P3 | Recruiting | Pneumococcal Disease | 3230 | 2029-06-05 |
| tilrekimig NCT07869043 |
P3 | Recruiting | Asthma | 1100 | 2029-06-07 |
| Etrasimod NCT05287126 |
P2 | Recruiting | Ulcerative Colitis | 36 | 2029-06-16 (+56 mo) |
| ELEVATE UC OLE NCT03950232 |
P3 | Active, not recruiting | Ulcerative Colitis | 896 | 2029-06-19 (+57 mo) |
| marstacimab NCT07923981 |
P3 | Recruiting | Hemophilia A or B | 95 | 2029-07-02 |
| KAT6 NCT04606446 |
P2 | Recruiting | Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer | 320 | 2029-08-27 (+60 mo) |
| CDK4i NCT04557449 |
P2 | Recruiting | Liposarcoma; Prostate Cancer | 430 | 2029-10-07 (+61 mo) |
| Palbociclib NCT05226871 |
P2 | Active, not recruiting | Breast Cancer; Head and Neck Cancer | 35 | 2029-12-31 (+44 mo) |
| PF-08634404 NCT07222800 |
P3 | Recruiting | Intestinal Neoplasms; Gastrointestinal Neoplasms | 800 | 2030-02-23 (-1 mo) |
| Rimegepant NCT06616194 |
P3 | Active, not recruiting | Migraine | 636 | 2030-02-26 (+27 mo) |
| PF-08634404 NCT07226999 |
P2/3 | Recruiting | Small Cell Lung Cancer (SCLC) | 550 | 2030-06-14 |
| B7981028 NCT07029828 |
P3 | Recruiting | Severe Alopecia Areata | 140 | 2030-06-26 |
| PF-06823859 NCT05895786 |
P3 | Recruiting | Myositis | 318 | 2030-07-29 (+56 mo) |
| Rimegepant (PF-07899801) NCT04743141 |
P3 | Recruiting | Acute Treatment of Migraine | 600 | 2030-07-31 (+82 mo) |
| PF-06741086 NCT05145127 |
P3 | Recruiting | Hemophilia A; Hemophilia B | 245 | 2030-07-31 |
| ELEVATE-UCkids NCT07470879 |
P2 | Recruiting | Colitis, Ulcerative | 24 | 2030-09-08 |
| MagnetisMM-6 NCT05623020 |
P3 | Recruiting | Multiple Myeloma | 1060 | 2030-10-18 (+28 mo) |
| COPD NCT07363694 |
P2/3 | Recruiting | Moderate to Severe Chronic Obstructive Pulmonary Disease | 1156 | 2030-10-24 |
| Osivelotor NCT05431088 |
P2/3 | Recruiting | Sickle Cell Disease | 389 | 2030-12-30 (+51 mo) |
| PF-08154225 NCT07782450 |
P1/2 | Not yet recruiting | Systemic Lupus Erythematosus; Rheumatoid Arthritis | 54 | 2031-02-22 |
| RSVpreF NCT07839871 |
P3 | Recruiting | Respiratory Syncytial Virus (RSV) | 920 | 2031-03-30 |
| C. difficile vaccine (previously studied formulation). NCT05805826 |
P1/2 | Active, not recruiting | Clostridoides Difficile Associated Disease | 936 | 2031-06-19 (+21 mo) |
| PF-08634404 NCT07392892 |
P2/3 | Recruiting | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma; Metastatic Gastric Cancer | 840 | 2031-07-22 |
| Dazukibart NCT06698796 |
P3 | Recruiting | Dermatomyositis; Polymyositis | 211 | 2031-07-29 (+45 mo) |
| Abrocitinib NCT06807281 |
P3 | Recruiting | Atopic Dermatitis | 450 | 2032-02-22 (+1 mo) |
| Atirmociclib NCT07890597 |
P3 | Not yet recruiting | Early Breast Cancer; Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | 3800 | 2032-04-13 |
| Inotuzumab ozogamicin NCT05748171 |
P2 | Recruiting | ACUTE LYMPHOBLASTIC LEUKEMIA | 100 | 2033-05-21 (+67 mo) |
| Tilrekimig NCT07839884 |
P3 | Not yet recruiting | Moderate to Severe Chronic Obstructive Pulmonary Disease | 1360 | 2034-05-12 |
| Testing of hepatic AAV Vector integration NCT05568719 |
P3 | Recruiting | Hemophilia A; Hemophilia B | 173 | 2040-02-25 (+66 mo) |